SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to the approval of its merger with Strive Enterprises, paving the way for a Bitcoin treasury company. The community is excited about the potential for a short squeeze, with some drawing comparisons to other high-flying crypto plays. With potential access to significant capital post-merger, discussions are centered around the stock's potential valuation and ability to outperform Bitcoin itself.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a surprise announcement of a warrant dividend for shareholders, sparking discussions around share lending and potential for a short squeeze. The community is analyzing the implications of these warrants, particularly how they may impact shorts and the stock's price movement. Positive earnings are adding fuel to the fire, with many expecting significant price swings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending following its earnings report, despite missing estimates, due to strong forward guidance and significant growth in cloud infrastructure revenue, particularly from multi-cloud databases. The community is focused on the company's massive backlog and potential for future growth in the AI space, leading to a debate about whether the stock's surge is justified or if it's a sign of a market bubble. Discussions also revolve around the potential impact on other tech stocks and Oracle's position in the cloud computing sector.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to a massive short squeeze following news of a new crypto treasury strategy, leading to extreme volatility and significant gains for some traders. Community discussions revolve around the potential for continued upward momentum versus an imminent pullback, with comparisons to other high-flying stocks in the sector. Speculation abounds regarding market manipulation and the risks associated with China-based stocks.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CWD is trending due to recent volatility, with community members discussing a potential pump and dump following the company's announcement of purchasing Chainlink tokens. Concerns about possible scams, dilution, and dark pool activity are circulating, while others hope for a short squeeze and recovery. The stock's dramatic price swings are drawing attention, with comparisons to other volatile stocks in the crypto space.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid growing investor interest in AI and e-commerce, with discussions around its potential for high growth and comparisons to other AI companies. The community is actively debating entry points, holding strategies, and the impact of upcoming earnings, while also highlighting the company's partnerships and patented technology. Some are expressing concerns about dilution and short selling, while others are very bullish for a run to double digits.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys is trending due to mixed reactions to its recent earnings report and future outlook, with investors focused on the company's exposure to macro uncertainties and the potential impact of its pending acquisition of Ansys. While some community members express confidence in the company's long-term prospects and AI-driven growth, others are concerned about the conservative guidance and its effect on the stock's valuation.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors discuss its upcoming earnings report and the potential impact on the stock's valuation, with the community weighing positive analyst sentiment against concerns about profitability. A key point of discussion revolves around the company's position in the cybersecurity sector relative to competitors and potential for long-term growth. Some traders are also focused on short-term strategies, anticipating volatility around the earnings release.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences, Inc. (REVB) on Tuesday announced positive safety and activity data from an early-stage trial of its investigational drug Gemini in stage 3 and 4 chronic kidney disease patients.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">trial </a>enrolled 40 patients aged 32 to 78 years. Different patients were treated at four different doses to evaluate the safety of Gemini, Revelation’s formulation of phosphorylated hexaacyl disaccharide, which aims to trigger the innate immune system to release pro-inflammatory cytokines and stimulate immune cell responses. Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli, the company said.However, shares of the company tumbled 17% at the time of writing, after the company reported that three severe adverse events were identified at the highest dose of Gemini in the study, including chills, nausea, and vomiting. However, this was all resolved in three hours or less, the company noted, while adding that other reported adverse events were either mild or moderate.On Stocktwits, retail sentiment around <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">REVB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_24_31_PM_png_d57363a4a3.webp" alt="REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user termed the news as “clear bullish” and opined that the stock could explode at any moment.<stembedurl>https://stocktwits.com/hassan101/message/627968361</stembedurl>Another user expressed surprise at the stock drop.<stembedurl>https://stocktwits.com/Chickendinner1/message/627961173</stembedurl>Revelation CEO James Rolke said that the results of the study demonstrate the potential of Gemini to be a “game-changer” in the treatment of acute and chronic inflammation. The company is now looking forward to a meeting with the FDA later this year to discuss the program's advancement, he added.Chronic kidney disease is caused by chronic inflammation. Progression of chronic kidney damage often leads to end-stage renal disease with the need for dialysis or transplantation, the company noted.REVB stock is down by about 89% this year and by about 94% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.

Equity

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.


Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split.&nbsp;The split is expected to be effective before the market opens on July 7.&nbsp;Revelation plans to conduct the reverse split to meet Nasdaq's minimum bid requirement.The reverse split, approved at a special shareholder meeting held on June 23, will affect all outstanding shares and adjust related equity instruments, including options, warrants, and restricted stock units (RSUs).&nbsp;Revelation will retain its current ticker symbol “REVB.”Separately, Revelation stated that enrollment is expected to conclude this month in its Phase 1b trial evaluating Gemini in patients with chronic kidney disease.&nbsp;Topline results are expected soon after.Earlier this year, the company said that Gemini reduced inflammation in lab tests involving human immune cells.&nbsp;Cells primed with Gemini showed lower levels of proinflammatory cytokines and higher levels of protective anti-inflammatory markers when exposed to known inflammation triggers, including HMGB-1 and bacterial LPS.&nbsp;The company said that similar effects could be observed in patients, supporting Gemini’s potential in treating inflammation-driven conditions.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.One user described the 1-for-3 reverse split as “small” and suggested that good news could follow shortly.&nbsp;<stembedurl>https://stocktwits.com/SkyLonger/message/619658091</stembedurl>Another user acknowledged the initial panic-driven selloff but argued the situation was different from typical reverse split moves, adding that “bigger news” may be on the way.<stembedurl>https://stocktwits.com/lookgoodplaygood22/message/619658026</stembedurl>Revelation’s stock has declined 92.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split. 

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 

FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports

Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.

Frasers Group decides not to make offer for Revolution Beauty

Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer   Revolution Beauty Group   PLC (LON:REVB).

Frasers explores potential bid for Revolution Beauty, company confirms

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the...

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the...

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following...

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of...

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

REVB
Revelation Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REVB News

REVB Revelation Biosciences Inc